Vor Biopharma (VOR) risk factors, FY2024 10-K

Risks Related to Our Financial Position and Need for Additional Capital

1. 01We have incurred significant net losses since inception. We expect to incur net losses for the foreseeable future and may never achieve or maintain profitability
2. 02operate as a public company
3. 03There is substantial doubt regarding our ability to continue as a going concern
4. 04We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our research and product development programs or future commercialization efforts
5. 05the costs of operating as a public company
6. 06Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
7. 07We have a limited operating history, have not yet completed any clinical trials and have no history of commercializing products, which may make it difficult to evaluate the success of our business to date and to assess our future viability
8. 08We have never generated revenue from product sales and may never become profitable
9. 09attract, hire and retain qualified personnel
10. 10Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset taxable income or taxes may be limited

Risks Related to Discovery, Development, Manufacturing and Commercialization

1. 11eHSCs is an emerging technology containing risk and might never lead to commercially viable products
2. 12establishing sales and marketing capabilities ahead of and after obtaining any regulatory approval to gain market acceptance, and obtaining coverage, adequate reimbursement and pricing by third-party payors and governmental healthcare programs
3. 13We are substantially dependent on the success of our two most advanced product candidates, trem-cel and VCAR33. If we are unable to complete development of, obtain approval for and commercialize trem-cel or VCAR33 in a timely manner, our business will be harmed
4. 14our ability to compete with other treatments
5. 15We may not be successful in our efforts to identify, develop and commercialize additional product candidates. If these efforts are unsuccessful, we may never become a commercial stage company or generate any revenues
6. 16our reputation may suffer
7. 17We are in the early stages of testing some of our product candidates in clinical trials and any favorable preclinical results are not predictive of results that may be observed in clinical trials
8. 18of product development. Any such adverse events may cause us to delay, limit or terminate planned clinical trials, any of which would have a material adverse effect on our business, financial condition, results of operations and prospects
9. 19Development of a product candidate such as trem-cel, which is intended for use in combination or in sequence with an already approved therapy, will present increased complexity and more or different challenges than development of a product candidate for use as a single agent
10. 20If we are unable to successfully develop our current programs into a comprehensive portfolio of product candidates, or experience significant delays in doing so, we may not realize the full commercial potential of our current and future product candidates
11. 21We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
12. 22Even if a product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success
13. 23If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing those product candidates if and when they are approved
14. 24unforeseen costs and expenses associated with creating an independent commercialization organization
15. 25Adverse public perception of genetic medicines, and of genome engineering in particular, including as a result of other trials out of our control, such as the VCAR33AUTO trial currently sponsored by NMDP, may negatively impact regulatory approval of, and/or demand for, our potential products
16. 26neither experimental nor investigational
17. 27biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical products, will apply to companion diagnostics
18. 28Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition
19. 29If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates
20. 30Insurance coverage is also increasingly expensive and we may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise
21. 31We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements
22. 32The process for treating cancer patients using T cell therapy or other cell-based targeted therapies is subject to human and systemic risks
23. 33Prior treatments can alter the cancer and negatively impact chances for achieving clinical activity with our CAR-T or other cell-based targeted therapies
24. 34We and any third-party manufacturers and any third-party collaborators may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing such product candidates and commercializing approved products, if any
25. 35We have not yet developed a validated methodology for freezing and thawing large quantities of eHSCs or of VCAR33, which we believe will be required for the storage and distribution of our product candidates, and we may face additional logistical challenges in the distribution of our product candidates
26. 36If we or any contract manufacturers and suppliers that we engage fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
27. 37Success in preclinical studies or clinical trials may not be indicative of results in future clinical trials, particularly for our clinical trials that involve only a small number of patients

Risks Related to Regulatory Review

1. 38Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates
2. 39disruption in the supply or availability of Mylotarg or any future targeted therapeutics we use with our eHSCs
3. 40experience damage to our reputation
4. 41the field of genome engineering is subject to a number of intellectual property disputes
5. 42changes to diagnostic technologies, methodologies or criteria used to identify HCT patients at high risk for relapse
6. 43If we are unable to successfully identify patients who are likely to benefit from our product candidates or eligible donors, or experience significant delays in doing so, we may not realize the full commercial potential of our product candidates
7. 44we may not realize the full commercial potential of any product candidates we develop that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from administration of our genetically engineered cells

Risks Related to Our Relationships with Third Parties

1. 45We rely on third parties for some aspects of our research and preclinical testing, and we rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing
2. 46form relationships with other entities, some of which may be our competitors
3. 47site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of our product candidates
4. 48reliance on the third party for regulatory compliance, quality assurance, safety and pharmacovigilance and related reporting
5. 49We have and may enter into collaborations with third parties for the research, development and commercialization of our product candidates. If any such collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates
6. 50Collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations
7. 51Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing
8. 52Collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation
9. 53Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates
10. 54If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans

Risks Related to Our Intellectual Property

1. 55We are highly dependent on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business
2. 56The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement
3. 57Our commercial success depends on our ability to obtain, maintain and protect our intellectual property and proprietary technology
4. 58countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates
5. 59The patent protection we obtain for our product candidates may not be sufficient to provide us with any competitive advantage or our patents may be challenged
6. 60in-licensed, though similar risks would apply to any patents or patent applications that we now own or may own or in-license in the future
7. 61the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized
8. 62If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed
9. 63We may not be successful in acquiring or in-licensing necessary rights to key technologies underlying our product candidates
10. 64Third-party claims of intellectual property infringement, misappropriation or other violations may prevent or delay our product discovery and development efforts and have a material adverse effect on our business
11. 65Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
12. 66We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful
13. 67Changes to patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
14. 68We may not be able to protect our intellectual property rights throughout the world
15. 69Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
16. 70If we do not obtain patent term extension and data exclusivity for trem-cel or any other product candidates, our business may be materially harmed
17. 71Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets
18. 72If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
19. 73Intellectual property rights do not necessarily address all potential threats

Risks Related to Regulatory and Other Legal Compliance Matters

1. 74Failure to obtain marketing approval in foreign jurisdictions would prevent product candidates from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue
2. 75injunctions or the imposition of civil or criminal penalties
3. 76transparency, health data privacy, and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research as well as market, sell and distribute our products for which we obtain marketing approval
4. 77Healthcare and other reform legislation, may increase the difficulty and cost for us and any collaborators we may have to obtain marketing approval of and commercialize our product candidates, if approved, and affect the prices we, or they, may obtain
5. 78Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
6. 79Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs

Risks Related to Employee Matters, Managing Growth and Information Technology

1. 80Our future success depends on our ability to retain our Chief Executive Officer and other key executives and to attract, retain and motivate qualified personnel
2. 81We expect to expand our development, regulatory and future sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
3. 82Our insurance policies may be inadequate and potentially expose us to unrecoverable risks

Risks Related to the Ownership of Our Common Stock

1. 83An active trading market for our common stock may not be sustained
2. 84The market price of our common stock may be volatile
3. 85the other factors described in this “Risk Factors” section
4. 86If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline
5. 87A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well
6. 88Insiders have substantial control over our company, which could limit the ability of our other stockholders to affect the outcome of key transactions, including a change of control
7. 89If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed
8. 90We are an “emerging growth company” and a “smaller reporting company,” and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors
9. 91We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices
10. 92Our management team has broad discretion in the use of our cash reserves and may not use them effectively
11. 93We do not expect to pay any dividends for the foreseeable future. Accordingly our stockholders must rely on capital appreciation, if any, for any return on their investment
12. 94Unfavorable global economic conditions, new tariffs or bank closures could adversely affect our business, financial condition or results of operations
13. 95Provisions in our certificate of incorporation and bylaws and under Delaware law could make a change in control of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
14. 96require the approval of the holders of at least 662⁄3% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws
15. 97any action asserting a claim against us that is governed by the internal-affairs doctrine